Åsberg Dennis, Nilsson Mikael, Olsson Susanne, Samuelsson Jörgen, Svensson Olof, Klick Silke, Ennis Julie, Butterworth Paul, Watt Denise, Iliadou Stavroula, Karlsson Angelica, Walker Joanne T, Arnot Kate, Ealer Norb, Hernqvist Kerstin, Svensson Karin, Grinell Ali, Quist Per-Ola, Karlsson Anders, Fornstedt Torgny
Department of Engineering and Chemical Sciences, Karlstad University, SE-651 88 Karlstad, Sweden.
Cambrex R & D, SE-691 33 Karlskoga, Sweden.
J Pharm Biomed Anal. 2016 Sep 10;129:273-281. doi: 10.1016/j.jpba.2016.06.018. Epub 2016 Jun 14.
Quality Control methods (QC-methods) play an important role in the overall control strategy for drug manufacturing. However, efficient life-cycle management and continual improvement are hindered due to a variety of post-approval variation legislations across territories and a lack of harmonization of the requirements. As a result, many QC-methods fall behind the technical development. Developing the QC-method in accordance with the Quality by Design guidelines gives the possibility to do continual improvements inside the original Method Operable Design Region (MODR). However, often it is necessary to do changes outside the MODR, e.g. to incorporate new technology that was not available at the time the original method was development. Here, we present a method enhancement concept which allows minor adjustments, within the same measuring principle, outside the original MODR without interaction with regulatory agencies. The feasibility of the concept is illustrated by a case study of a QC-method based on HPLC, assumed to be developed before the introduction of UHPLC, where the switch from HPLC to UHPLC is necessary as a continual improvement strategy. The concept relies on the assumption that the System Suitability Test (SST) and failure modes are relevant for other conditions outside the MODR as well when the same measuring principle is used. It follows that it should be possible to move outside the MODR as long as the SST has passed. All minor modifications of the original, approved QC-method must be re-validated according to a template given in the original submission and a statistical equivalence should be shown between the original and modified QC-methods. To summarize, revalidation is handled within the pharmaceutical quality control system according to internal change control procedures, but without interaction with regulating agencies.
质量控制方法(QC 方法)在药品生产的整体控制策略中发挥着重要作用。然而,由于各地区各种批准后变更法规以及要求缺乏协调统一,有效的生命周期管理和持续改进受到阻碍。因此,许多 QC 方法落后于技术发展。按照质量源于设计指南开发 QC 方法,使得在原始方法可操作设计区域(MODR)内进行持续改进成为可能。然而,通常有必要在 MODR 之外进行变更,例如纳入原始方法开发时不可用的新技术。在此,我们提出一种方法增强概念,该概念允许在相同测量原理下,在原始 MODR 之外进行微小调整,而无需与监管机构进行交互。通过一个基于 HPLC 的 QC 方法的案例研究说明了该概念的可行性,假设该方法是在 UHPLC 引入之前开发的,作为持续改进策略,从 HPLC 切换到 UHPLC 是必要的。该概念基于这样的假设:当使用相同测量原理时,系统适用性测试(SST)和失效模式对于 MODR 之外的其他条件也同样相关。由此可知,只要 SST 通过,就应该有可能在 MODR 之外进行操作。对原始批准的 QC 方法的所有微小修改都必须根据原始提交文件中给出的模板重新进行验证,并且应显示原始 QC 方法和修改后的 QC 方法之间的统计等效性。总之,重新验证是根据内部变更控制程序在药品质量控制系统内进行处理的,但无需与监管机构进行交互。